People with lupus do have a higher risk of developing certain cancers compared to the general population. Across large studies, the overall cancer risk is about 62% higher for people with systemic lupus erythematosus (SLE). That elevated risk isn’t spread evenly across all cancer types. It concentrates in blood cancers, particularly lymphoma, and in a handful of solid tumors including lung, kidney, and thyroid cancers.
How Much Higher Is the Risk?
A meta-analysis pooling data from over 230,000 lupus patients found that overall cancer risk was 1.62 times that of the general population. To put that in perspective, if 100 out of every 10,000 people in the general population develop a given cancer over a certain period, roughly 162 out of 10,000 lupus patients would. It’s a meaningful increase, but it does not mean cancer is inevitable or even likely for any individual person with lupus.
The sharpest spike shows up in blood cancers. A large international study tracking more than 16,000 lupus patients confirmed a threefold increased risk for blood cancers, with lymphoma (especially non-Hodgkin lymphoma) standing out as the most consistently elevated. Among solid tumors, a California cohort of over 30,000 lupus patients found roughly double the risk for lung cancer, kidney cancer, and thyroid cancer compared to the general state population.
Interestingly, some cancers are actually less common in people with lupus. Breast, cervical, and prostate cancers all appeared at lower rates in that same California study. The cervical cancer finding was somewhat surprising, since women with lupus tend to have higher rates of HPV infection, which normally drives cervical cancer risk up. Researchers haven’t fully explained why the expected increase doesn’t materialize.
Why Lupus Raises Cancer Risk
There is no single explanation. Instead, several overlapping biological processes create a higher-risk environment in people living with lupus.
Chronic Immune Activation
Lupus keeps the immune system in a state of constant overdrive. That persistent stimulation forces immune cells, particularly B cells, to divide rapidly and repeatedly. Each round of division introduces opportunities for genetic errors to accumulate. Over time, this can push a normal immune cell toward becoming a cancerous one. Genetic variations that increase inflammatory signaling (like certain changes in TNF-alpha, a key inflammation molecule) appear to further raise the odds by helping abnormal cells survive longer than they should.
This mechanism is especially relevant to non-Hodgkin lymphoma. When B cells enter the lymph nodes and respond to what the immune system perceives as a threat, they undergo rapid changes to become more specialized. In lupus, this process is essentially always running. The subtype of lymphoma most commonly linked to lupus, diffuse large B-cell lymphoma, derives from these activated B cells, suggesting it’s a downstream consequence of relentless inflammation.
Viral Reactivation
Epstein-Barr virus (EBV), the virus behind mononucleosis, plays a role. Most adults carry EBV in a dormant state, and a healthy immune system keeps it in check. In lupus, the specific branch of the immune system responsible for suppressing EBV (certain T cells) doesn’t work as effectively. This allows the virus to reactivate more frequently. When EBV infects B cells during these reactivations, it ramps up production of an enzyme that accelerates genetic mutations in those cells, further raising the chance of lymphoma.
Organ-Level Inflammation
For lung cancer specifically, the link may run through lung damage. Lupus can cause chronic inflammation in lung tissue and, in some cases, pulmonary fibrosis (scarring). This ongoing cycle of tissue damage and repair creates conditions where DNA damage accumulates in lung cells, a pattern also seen in people with other forms of lung fibrosis who develop lung cancer at elevated rates.
The Role of Lupus Medications
Some lupus treatments themselves influence cancer risk, in both directions. A study of nearly 15,000 lupus patients found that cumulative exposure to cyclophosphamide, a powerful immunosuppressant used for severe lupus (especially kidney involvement), was associated with a dose-dependent increase in cancer risk. For every unit increase in cumulative dose, risk rose by about 9%.
Hydroxychloroquine told the opposite story. Higher cumulative doses were linked to a 7% reduction in cancer risk per unit increase. This protective effect makes hydroxychloroquine’s already well-established role as a cornerstone of lupus treatment even more significant. If you’re taking it, this is one more reason to stay consistent with it.
The takeaway isn’t that immunosuppressive medications are dangerous and should be avoided. Uncontrolled lupus causes serious organ damage, and the treatments that prevent that damage are necessary. But these findings do help explain why cancer risk varies among lupus patients: someone who has needed intensive immunosuppression for years faces a different risk profile than someone whose disease has been managed with milder therapies.
Skin Cancer and Sun Exposure
Lupus and skin cancer share a common trigger: ultraviolet light. Sunlight is one of the most reliable triggers for lupus flares, and it’s also the primary environmental cause of skin cancer. The Johns Hopkins Lupus Center recommends that people with lupus avoid sun exposure whenever possible and use sunscreen with SPF 85 or higher that blocks both UV-A and UV-B rays. This advice serves double duty, protecting against both flares and skin damage that could become cancerous over time.
Cancer Outcomes Are Worse With Lupus
The risk of getting cancer is only part of the picture. When people with lupus do develop cancer, they tend to fare worse than cancer patients without lupus. In one study comparing lupus patients who developed malignancies to matched controls with the same cancers, 15-year survival was 27.1% for the lupus group versus 52.4% for the non-lupus group. The risk of death was nearly 70% higher for lupus patients with cancer.
Several factors likely contribute to this gap. Lupus itself places ongoing stress on the cardiovascular system and kidneys, which can complicate cancer treatment. Immunosuppressive medications used for lupus may need to be adjusted during chemotherapy, creating difficult tradeoffs. And the immune dysfunction at the core of lupus may impair the body’s ability to mount an effective response against tumor cells, even with treatment.
Malignancy was the most common cause of death in both groups, accounting for 70% of deaths in lupus patients with cancer and 76% in controls. But cardiovascular disease claimed a larger share of lupus patients (19%) compared to controls (9%), reflecting the broader cardiovascular burden that lupus carries.
What This Means in Practice
A 62% increased overall cancer risk sounds alarming in isolation, but it helps to remember that baseline cancer risk for most types is relatively low. The increase shifts your risk from low to slightly less low, not from safe to dangerous. Where the risk becomes more clinically significant is in specific categories: lymphoma, lung cancer if you have lupus-related lung disease, and situations involving long-term use of certain immunosuppressants.
Staying on hydroxychloroquine, keeping up with age-appropriate cancer screenings, protecting your skin from UV exposure, and working with a rheumatologist who monitors your medication exposure over time are all practical steps that address the risk factors you can actually influence. If you’ve had extensive immunosuppressive treatment or have active lung involvement from lupus, those are worth flagging with your care team as factors that might warrant closer surveillance.